Navigating 6 Analyst Ratings For Moderna
Portfolio Pulse from Benzinga Insights
In the past three months, Moderna (NASDAQ:MRNA) received mixed analyst ratings, ranging from bullish to bearish, with a notable upward trend in the 12-month price targets, now averaging $119.17. Recent analyst actions include ratings and price target adjustments by firms such as Oppenheimer and Jefferies, reflecting changing market dynamics and Moderna's performance. Despite challenges in revenue growth and profitability indicators, Moderna's market presence remains strong, supported by its mRNA technology and a diverse clinical trial pipeline.
May 03, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna has received mixed analyst ratings but shows a positive trend in price targets, indicating a bullish outlook from some analysts despite recent revenue and profitability challenges.
The upward revision in price targets by analysts such as Oppenheimer and Jefferies, despite Moderna's recent revenue decline and below-average profitability metrics, suggests a belief in the company's long-term growth potential. This is further supported by Moderna's strong market presence and its extensive mRNA technology pipeline. The mixed ratings reflect a cautious optimism, acknowledging both the challenges and the opportunities ahead for Moderna.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100